Research progress on antiviral therapy in severe hepatic impairment patients and special population with HCV infection
10.3760/cma.j.issn.1674-2397.2018.05.003
- VernacularTitle:HCV感染重症肝病患者和特殊人群抗病毒治疗的若干进展
- Author:
Kezhou LIU
1
Author Information
1. 浙江大学医学院附属第一医院传染病诊治国家重点实验室
- Keywords:
Hepatitis C;
chronic;
Direct-acting antiviral agents;
Genotype;
Decompensated cirrhosis;
Special patients
- From:
Chinese Journal of Clinical Infectious Diseases
2018;11(5):339-345
- CountryChina
- Language:Chinese
-
Abstract:
The research and development of direct-acting antiviral agents (DAAs) for hepatitis C achieved significant results in the last decade .DAAs is highly effective in treatment of hepatitic C patients with convenience and safety , and the sustained virological response of DAAs is over 90％, which will greatly contribute to achieving the WHO's goal of eliminating hepatitis C by 2030.The European Association for the Study of the Liver (EASL), American Association for the Study of Liver Diseases (AASLD) and WHO all updated guidelines for diagnosis and treatment of hepatitis C in 2018, which will play a positive role for the management of hepatitis C globally .This article reviews the related guidelines and literature on prevention and treatment of hepatitis C , and summarizes the advantages of antiviral therapy for severe hepatic impairment patients and special population with HCV infection .
